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Allergic asthma is a complex inflammatory disorder characterized by airway hyperresponsiveness, 
eosinophilic inflammation and hypersecretion of mucus. Current therapies include β2-agonists, cysteinyl 
leukotriene receptor 1 antagonists and corticosteroids. Although these drugs demonstrate beneficial 
effects, their adverse side effects limit their long-term use. Thus, the development of new compounds 
with similar therapeutic activities and reduced side effects is both desirable and necessary. Natural 
compounds are used in some current therapies, as plant-derived metabolites can relieve disease symptoms 
in the same manner as allopathic medicines. Quercetin is a flavonoid that is naturally found in many 
fruits and vegetables and has been shown to exert multiple biological effects in experimental models, 
including the reduction of major symptoms of asthma: bronchial hyperactivity, mucus production and 
airway inflammation. In this review, we discuss results from the literature that illustrate the potential of 
quercetin to treat asthma and its exacerbations.
Uniterms: Quercetin. Flavonoids. Asthma. 
A asma alérgica é uma doença inflamatória complexa caracterizada por hiperresponsividade das vias 
aéreas, inflamação eosinofílica e hipersecreção de muco. As terapias atuais incluem β2-agonistas, 
antagonistas do receptor 1 de cisteinil leucotrienos e corticosteróides. Embora estes fármacos demonstrem 
efeitos benéficos, seus efeitos adversos limitam seus usos a longo prazo. Assim, o desenvolvimento de 
novos compostos com atividades terapêuticas similares e reduzido efeitos adversos é tanto desejável 
quanto necessário. Compostos naturais podem ser utilizados nas terapias atuais, uma vez que metabólitos 
derivados de plantas são capazes de aliviar os sintomas de forma comparável aos medicamentos alopáticos. 
A quercetina é um flavonóide que ocorre naturalmente em muitas frutas e vegetais e tem mostrado 
vários efeitos biológicos, principalmente em modelos experimentais, incluindo a redução dos principais 
fenótipos da asma: hiperreatividade brônquica, produção de muco e inflamação das vias aéreas. Nesta 
revisão, nós discutimos os resultados da literatura que revelam o potencial da quercetina para tratar a 
asma e suas exacerbações.
Unitermos: Quercetina. Flavonóides. Asma.
INTRODUCTION
Asthma is a chronic inflammatory disease com-
mon worldwide (Mukherjee, Zhang, 2011). According 
to the guidelines issued by the U.S. National Heart, Lung 
and Blood Institute and the Global Initiative for Asthma 
(GINA), asthma severity can be classified based on clini-
cal features into intermittent, mild persistent, moderate 
persistent, and severe persistent asthma (Wenzel, 2006). 
The most common signs of asthma include airway ob-
struction, wheezing and airway hyperresponsiveness 
(Bousquet et al., 2000). In addition, patients also exhibit 
airway inflammation characterized by the recruitment of 
eosinophils and other leukocytes, airway smooth muscle 
hypertrophy/hyperplasia, systemic IgE production and 
mucus hypersecretion.
The pathophysiology of allergic asthma is mediated 
by CD4+ T cell immune responses. T helper (Th) 1 and 
Th17 cells promote neutrophil recruitment and have been 
associated with both severe and steroid-resistant asthma. 
Th9 cells have been shown to affect mucus production, 
mast cell recruitment and IgE production. CD8+ T cells, 
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NKT cells and gd T cells are also able to modulate asthma-
associated inflammation and/or airway hyperresponsive-
ness (AHR). In contrast, Treg cells are known to suppress 
innate and adaptive immune responses and decrease 
inflammation. Although knowledge regarding the roles 
of different T cell subsets in the asthma has increased in 
recent years, Th2-type immune responses are most clas-
sically associated with the pathology of asthma (Lloyd, 
Hessel, 2010).
Asthma exacerbations are common, and their pre-
vention and treatment are perhaps the most important 
clinical issues for optimal asthma control (Messer et al., 
2010). Episodes of asthma exacerbation can be triggered 
by allergen inhalation, viruses, pollutant exposure, ex-
ercise, non-steroidal anti-inflammatory medications and 
occupational agents (Chua, Lai, 2007; Tillie-Leblond et 
al., 2005). In episodes of asthma exacerbation, in addition 
to eosinophils, neutrophils are recruited to the airway. In 
fact, neutrophils are the most prevalent inflammatory cell 
population in the airways of individuals who have died 
from asthma attacks (Sur et al., 1993).
Typical asthma treatments include β2-agonists and 
systemic corticosteroids (Mukherjee, Zhang, 2011; NIH, 
1997). Administration of nebulized β2-agonists (continu-
ous or repetitive), such as salbutamol, causes broncho-
dilation and is considered a first-line treatment for the 
management of asthma (NIH, 1997; Wort, 2003). Corti-
costeroids are the most commonly prescribed therapeutics 
for controlling nearly all types of inflammatory reactions 
and exert strong effects on leukocyte recruitment when 
administered orally or systemically (Harris, 1972; Flower, 
1988; Perretti, Flower, 1993). The most striking effect of 
corticosteroids is their ability to inhibit the expression of 
multiple inflammatory mediators whose genes are regu-
lated by transcription factors, such as nuclear factor-kB 
(NF-kB) (Barnes, 1998). Thus, inhibition of the NF-kB 
pathway is associated with decreased expression of genes 
encoding cytokines (e.g., IL-5), chemokines (e.g., eotax-
ins) and adhesion molecules (e.g., E-selectin), all of which 
play critical roles in regulating eosinophil recruitment 
(Rabier et al., 1991; Faccioli et al., 1996). Inhibitors of LT 
synthesis (such as zileuton, which directly inhibits 5-LO) 
or CysLT1 antagonists (such as montelukast, zafirlukast, 
and pranlukast) may also be used as complementary thera-
pies to treat asthma, reducing the requirement for corti-
costeroids (Salvi et al., 2001; Peters-Golden, Henderson, 
2007; Montuschi et al., 2007).
Although the drugs described above have potent 
effects when used individually or in combination, they 
also have adverse side effects that limit their long-term 
use (Papiris et al., 2009). Prolonged use of corticosteroids 
can lead to iatrogenic Cushing’s syndrome, osteoporosis, 
susceptibility to infections, and psychiatric disorders, 
along with various other disorders (Macfarlane, Forbes, 
Walker, 2008; Dias et al., 2010). Increased cardiovascular 
complications in patients who use β2-agonists might be the 
consequence of increased heart rates and reduced potas-
sium levels (Salpeter, Ormiston, Salpeter, 2004; Cazzola, 
Matera, Donner, 2005). Usage of inhibitors of LT synthesis 
has been associated with headaches and gastrointestinal 
disturbances (Cung, 1995). Thus, it is necessary to de-
velop new compounds with similar therapeutic potential 
and less adverse effects for the continuous treatment of 
airway diseases. 
Agents of natural origin that induce very few side 
effects should be considered for therapeutic substitution 
or as complementary treatments. Furthermore, natural 
compounds may serve as the basis for new drugs in the 
treatment of many diseases (Verpoorte, 1999). In an on-
going search for bioactive plant-derived natural products, 
several groups, including ours, have successfully em-
ployed experimental methods to screen plant extracts and 
plant secondary metabolites for pharmacological activity. 
In addition, several groups have also demonstrated the ef-
fectiveness of extracts from plants, such as Ginkgo biloba 
and Hypericum perforatum, in clinical trials (Wadsworth 
et al., 2001, Canning et al., 2010).
The earliest written records on the use of medicinal 
plants were found in Assyrian clay tablets (2000 BC), 
the Egyptian Ebers Papyrus (1550 BC) and in Ayurveda 
works from 900 BC. Moreover, Hippocrates, Dioscorides, 
Galen, Paracelsus and Arab scholars in Europe preserved 
knowledge regarding the use of medicinal plants (Sneader, 
2005; Potterat, Hamburger, 2008). The origin of research-
ing natural products in the pharmaceutical industry began 
with the isolation of morphine from opium latex in 1805 by 
Sertürner (Potterat, Hamburger, 2008). However, the most 
famous product of plant origin, which was discovered the 
19th century, is acetylsalicylic acid (ASA), a derivative 
of salicylic acid extracted from willow bark (Salix alba 
and other species) (Rainsford, 2007). Patented by Bayer 
in 1900 and sold under the brand name Aspirin, ASA is 
primarily used to treat pain and inflammation.
Several plant-derived secondary metabolites can 
decrease the expression and production of inflammatory 
mediators and their receptors, down-regulate the produc-
tion and activity of second messengers and inhibit the 
expression of transcription factors that promote the pro-
duction of inflammatory molecules (Calixto et al., 2000, 
2004). Such effects provide symptom relief similar to 
that afforded by allopathic medicines. Flavonoids are the 
most studied class of plant metabolites. The search term 
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“flavonoids” yielded more than 57,300 entries in the U.S. 
National Library of Medicine’s Medline database accessed 
using PubMed in December 2011.
Flavonoids are a family of plant compounds with 
a similar flavone backbone composed of two aromatic 
rings and an oxygen heterocycle with hydroxyl groups 
attached. There are many classes of flavonoids, such as 
flavones, flavanones, isoflavones, flavonols, flavanonols, 
flavan-3-ols, and anthocyanidins. Flavonoid molecules 
may or may not be attached to sugars. Compounds con-
taining no sugars are known as aglycones (Pietta, 2000). 
The quercetin aglycone is a flavonol that occurs naturally 
in fruits and vegetables, including onions, apples, grapes 
and nuts. Therefore, it is commonly included in human 
diets (Middleton et al., 2000). Quercetin may have already 
been used in treating human disease (phytotherapy), as it 
is present in the seeds, stems, barks, roots and/or flowers 
of several medicinal plants.
Typically, quercetin is linked to sugars, such as 
glucose (quercetin-3-glucoside, isoquercitrin) or rutinose 
(rutin). However, after ingestion, enzymes in the mouth 
and the intestines hydrolyze quercetin glycosides to quer-
cetin aglycones (Egert et al., 2010; Perez-Vizcaino et al., 
2009). Interestingly, quercetin and its metabolites have 
been observed in the lungs of rats (De Boer et al., 2005). 
In human, quercetin metabolites have also been found to 
be present in the carbon dioxide (CO2) exhaled from the 
lung (Walle et al., 2001).
POTENTIAL EFFECTS OF QUERCETIN ON 
ASTHMA
Quercetin has a wide range of therapeutic properties, 
including, but not limited to, its antioxidant, anti-cancer, 
anti-inflammatory and anti-allergic activities. Recently, 
key findings have been made regarding the effects of 
quercetin on the airway (Figure 1).
Mast cells play an important role in the early and 
late phases of asthma, as they release several mediators, 
including histamine, leukotrienes and cytokines, which 
modulate airway hyperreactivity and inflammation. IgE 
binds to mast cells and basophils through their high-affini-
ty IgE Fc receptor (FcεRI) (Gould, Sutton, 2008; Furuichi, 
Rivera, Isersky, 1985), and subsequent exposure to antigen 
induces IgE-sensitized mast cell degranulation. During 
degranulation, both pre-formed and newly generated me-
diators are released. These mediators, either alone or in 
conjunction with Th2 cytokines, increase smooth muscle 
cell contractility, epithelial cell permeability and mucus 
production. Furthermore, mast cell degranulation triggers 
the recruitment of macrophages, eosinophils and basophils 
to the inflammatory site (Holgate, Polosa, 2008). Previous 
findings have shown that treatment with quercetin inhibits 
the release of histamine and pro-inflammatory mediators 
(TNF-α, IL-1β, IL-6 and IL-8) from mast cells stimulated 
with IgE (Cruz et al., 2012; Park et al., 2008; Kempuraj 
et al., 2005), likely due to inhibition of NF-kB and p38 
mitogen-activated protein kinase (p38 MAPK) (Min et 
al., 2007). Thus, quercetin demonstrates the potential to 
modulate the early and late phases of asthma.
A systematic review conducted by our group 
showed the anti-eosinophilic effects of medicinal plants 
and plant-derived substances in eosinophilic models, 
including models of acute peritonitis induced by either 
the polysaccharide-rich F1 fraction from Histoplasma 
capsulatum yeast or by Toxocara canis helminth infection, 
also known as visceral larva migrans syndrome (VLMS) 
or toxocariasis, and the classical ovalbumin-induced al-
lergic asthma model (Rogerio, Sá-Nunes, Faccioli, 2010). 
Eosinophils produce cytokines (e.g., IL-4, IL-5 and IL-13), 
chemokines (e.g., CCL11) (Perretti, Flower, 1993; Barnes, 
1998; Barnes, 2006), lipid mediators (LTB4) and principal 
cationic proteins (major basic protein, eosinophil-derived 
neurotoxin, eosinophil cationic protein and eosinophil 
peroxidase) that can exacerbate airway inflammation and 
cause tissue damage (Rothenberg, Hogan, 2006; Gleich, 
Loegering, 1984). Our group was the first to demonstrate 
that quercetin (10 mg/kg; oral dose) reduces eosinophils 
in the blood, bronchoalveolar lavage fluid (BALF) and the 
pulmonary parenchyma in a murine model of ovalbumin-
induced allergic airways inflammation (Rogerio et al., 
2007). Interestingly, in this study, isoquercitrin (quercetin 
attached to glucose) was more efficient than quercetin 
aglycone in decreasing IL-5 concentrations in the BALF. 
IL-5 is the main cytokine involved in blood eosinophilia 
during both allergic inflammation and parasitic infec-
tion. This cytokine is essential for eosinophil migration 
from the bone marrow to the blood (Faccioli et al., 1996; 
Sanderson et al., 1985), and it specifically supports the 
terminal differentiation and proliferation of eosinophil 
precursors. Additionally, IL-5 activates mature eosinophils 
(Yamaguchi et al., 1988; Clutterbuck, Sanderson, 1988). 
Similar results were found by other groups employing the 
same experimental models in mice and guinea pigs but 
using different routes of quercetin administration (intra-
peritoneal or aerosol route) (Moon et al., 2008; Jung et al., 
2007; Park et al., 2009). Quercetin has also demonstrated 
the potential to reduce airway hyperresponsiveness, bron-
chial hyperactivity (Ko et al., 2004; Jiang et al., 2007) and 
mucus production (Chang et al., 2010).
Despite its potential systemic anti-inflammatory 
property, quercetin aglycone is known to be poorly soluble 
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in water. Previous findings have shown that it is less ab-
sorbed than quercetin glycosides and that its absorption 
seems to depend on the type and position of the sugar 
moieties (Hollman et al., 1995; Hollman et al., 1997). 
In the above studies, dimethyl sulfoxide (DMSO) and 
polyethylene glycol were used as adjuvants to improve 
quercetin solubilization and absorption. However, these 
substances are not approved for human use.
Colloidal drug delivery systems, such as microemul-
sions, have been proposed to improve the absorption and 
therapeutic index of several drugs (Gupta et al., 2005). 
Microemulsions are isotropic liquid mixtures of oil, water 
and surfactant frequently found in combination with a 
co-surfactant and are translucent and thermodynamically 
stable. The dispersed phase, generally lipophilic, acts 
as a potential reservoir of lipophilic drugs that, when it 
contacts semi-permeable membranes, such as skin or a 
mucous membrane, can facilitate the transport of drugs 
through these barriers (Formariz et al., 2007; Vicentini 
et al., 2008).
In a murine model of ovalbumin-induced allergic 
airway inflammation, treatment with a quercetin-loaded 
microemulsion (QU-ME) was more effective than quer-
cetin suspension (QU-SP) and reduced eosinophil recruit-
ment; decreased the production of IL-4, IL-5, CCL11 and 
LTB4; inhibited mucus production; and down-modulated 
P-selectin expression by blocking NF-kB signaling. Under 
inflammatory conditions, IL-5 and the eotaxins CCL11, 
CCL24 and CCL26 have been shown to cooperate in se-
lectively recruiting eosinophils (Jose et al., 1994; Rothen-
berg et al., 1995). IL-4 and IL-13 are potent inducers of 
eotaxins. Additionally, when administered exogenously, 
eosinophils collaborate with IL-5 to induce IL-13 pro-
duction in the lungs (Zimmermann et al., 2003). LTB4, 
FIGURE 1 – Possible effects and mechanisms of quercetin activity during asthma. Previous findings have shown that quercetin 
inhibits mast cell degranulation (A), reduces airway hyperreactivity (B), reduces mucus production (C), causes decreases in 
eosinophil and neutrophil recruitment (D), modulates Th1/Th2 cytokine production (E), demonstrates anti-fibrotic activities (F) 
and reduces collagen deposition (G). These effects might be associated with attenuation of the PI3-kinase, Akt and NF-kB signaling 
pathways (H).
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a lipoxygenase (LO)-derived product, is also involved 
in the activation and chemotaxis of eosinophils, among 
other cells (Peters-Golden, Henderson, 2007). Thus, the 
higher efficacy of QU-ME was due to the increased oral 
absorption of quercetin and, consequently, the reduction 
of cytokines, chemokines and lipid mediators involved in 
trafficking of eosinophils into inflammatory sites (Rogerio 
et al., 2010).
In the inflammation associated with asthma, the ex-
pression of multiple inflammatory mediators is regulated 
by transcription factors. The T-box and GATA family of 
transcription factors plays several roles in hematopoiesis 
and is active in many cell lineages, including T cells. 
While the upregulation of GATA-3 promotes Th2 cell 
differentiation (Barnes, 2011), the expression of T-bet is a 
determinant for Th1 cell differentiation (Lazarevic, Glim-
cher, 2011). Quercetin suppressed GATA-3 and increased 
T-bet expression in a murine model of ovalbumin-induced 
allergic airway inflammation. Consequently, quercetin 
reduced IL-4 and increased IFN-g concentration in the 
BALF of these animals (Park et al., 2009). IL-4 is primar-
ily responsible for the development of Th2-type immune 
responses. In contrast, IFN-g, a Th1 cytokine, inhibits Th2 
immune responses and may provide some rationale for the 
outcome of allergic airway inflammation (Saggini et al., 
2011). These results demonstrate that quercetin is able to 
modulate Th1/Th2 cytokine production and consequently 
asthma pathology.
Currently, many questions still remain concerning 
the nature of the inflammatory process in severe episodes 
of asthma exacerbation. In addition to eosinophils, neu-
trophils are also important cells that release oxidative 
products, eicosanoids and metalloproteinases (specifically 
MMP-9), which contribute to lung epithelial and endothe-
lial cell injury and increase vascular permeability. Inter-
estingly, tissue inhibitor of metalloproteinase (TIMP)-1, 
an inhibitor of MMP-9, is reduced in the plasma and the 
bronchi of patients with asthma (Belleguic et al., 2002). 
In an experimental model of airway inflammation induced 
by the intranasal administration of elastase and LPS, 
quercetin inhibited neutrophil recruitment and MMP-9 
and MMP-12 expression and activity both in vivo and in 
vitro (Ganesan et al., 2010). Taken together with other 
published results, these findings suggest potential ben-
eficial effects of quercetin treatment on asthmatic airway 
inflammation.
The airway epithelium’s function is to transport air 
into the alveoli and to protect the lungs against patho-
gens, allergens and inhaled environmental particulates 
through the secretion of antimicrobial molecules and 
pro-inflammatory cytokines and chemokines. In addition, 
the airway epithelium also has the ability to modulate the 
function of lung dendritic cells, which are essential in 
initiating inflammation and determining the type of ef-
fector immune response (Th1, Th2 or Th17) (Belleguic et 
al., 2002; Ganesan et al., 2010). Treatment with quercetin 
prior to TNF-α stimulation reduced the expression of IL-8 
and chemokines (C-C motif) ligand 2 (CCL2/MCP-1) in 
bronchial epithelial cells (Nanua et al., 2006), which are 
involved in asthma pathogenesis (Romagnani, 2002). This 
effect was associated with attenuation of the PI3-kinase, 
Akt and NF-kB signaling pathways. Several other studies 
have also demonstrated this effect of quercetin on NF-kB 
reduction (Nam, 2006; Rahman, Adcock, 2006).
Adhesion molecules are involved in the control of 
leukocyte influx. Expression of intercellular adhesion mol-
ecule-1 (ICAM-1), an adhesion molecule that participates 
in cell-cell and cell-matrix adhesive interactions, has been 
associated with several inflammatory diseases, including 
asthma (Stanciu, Djukanovic, 1998). Quercetin has been 
shown to reduce ICAM-1 expression on a pulmonary 
epithelial cell line (A549) in a dose-dependent manner, 
and decreased ICAM-1 expression has been shown to be 
mediated through inhibition of the NF-kB, ERK-1/2 and 
JNK signaling pathways (Ying et al., 2009). Thus, quer-
cetin’s effect in reducing leukocyte recruitment may be 
associated with a reduction in chemokines and adhesion 
molecules. In addition to epithelial cells, fibroblasts are 
also involved in asthma pathogenesis.
Fibroblasts are responsible for the synthesis of col-
lagen, with human fibroblasts synthesizing both type I and 
type III collagen. Repetitive injury of the alveolar-capil-
lary membrane results in a loss of basement membrane 
integrity, and the subsequent activation of fibroblasts and 
myofibroblasts can lead to fibrosis. In the lungs, fibro-
blast accumulation and abnormal remodeling can result 
in respiratory failure (Bousquet, Yssel, Vignola, 2000). 
Studies have shown that quercetin exhibits potent anti-
fibrotic effects in the lungs (Nakamura et al., 2011; Qi 
et al., 2001). Treatment with liposomal quercetin in a rat 
bleomycin-induced pulmonary fibrosis model suppressed 
lung hydroxyproline content and collagen deposition 
(Baowen et al., 2010). Quercetin also decreased type I 
and type III collagen synthesis in both keloid and normal 
fibroblasts in a dose-dependent manner (Long et al., 2006). 
Heme oxygenase (HO)-1, an inducible stress protein, has 
been suggested to confer protection in diseases associated 
with lung injury. Nakamura et al. (2011) demonstrated 
that quercetin reduced fibroblast collagen deposition by 
inducing HO-1 upregulation. In another study using a 
murine model of experimental infection with Schistosoma 
japonicum, quercetin inhibited liver fibrosis (Xu et al., 
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2006). These results suggest that quercetin might modulate 
airway remodeling in asthmatic patients. Interestingly, 
quercetin acts as a potent bronchodilator in vitro (tracheal 
smooth muscle) and in vivo (guinea pigs sensitized with 
ovalbumin) (Joskova et al., 2011).
In humans, there is some correlation between an 
increased risk for several chronic diseases and a lower 
dietary flavonoid intake. For instance, the incidence of 
asthma is lower in individuals who ingested higher quan-
tities of total flavonoids, including quercetin (Knekt et 
al., 2002). Quercetin has been present in the human diet 
throughout the history of humanity, and it is currently used 
as a food additive (Harwood et al., 2007). Daily oral intake 
of quercetin can range from 5 to 500 mg, depending on 
the individual’s consumption of quercetin-rich fruits and 
vegetables, such as tomatoes and onions. Several epide-
miological studies and clinical trials as well as animal and 
in vitro studies have been performed to evaluate the safety 
of quercetin. Nearly all reports found little association 
between dietary quercetin consumption and an increased 
risk of cancer or other adverse health effects (Harwood et 
al., 2007; Okamoto, 2005). However, quercetin, similar to 
other substances, may interfere with the pharmacokinetics 
of other medicines, such as digoxin, which could lead to 
significant adverse events (Wang et al., 2004). Evidence 
also suggests that quercetin may reduce the bioavailability 
of cyclosporine, simvastatin and other drugs. Therefore, 
although quercetin itself causes no direct significant side 
effects, it may give rise to indirect side effects when used 
in combination with other drugs. Thus, quercetin should 
be administered carefully if given concomitantly with 
other medications. However, no interactions have been 
described regarding the concomitant use of quercetin with 
drugs, such as β2-agonists and corticosteroids, that are 
currently used to treat asthma.
CONCLUSION
Asthma and its primary exacerbations demonstrate 
high morbidity, mortality and health care costs. In addi-
tion, some patients are refractory to the current therapies 
of β2-agonists and corticosteroids, whose adverse side ef-
fects limit their long-term use. Quercetin, which has been 
widely consumed in the diet since the beginnings of human 
history, has significant biological effects with no known 
significant adverse side effects. Quercetin demonstrates 
the potential to reduce the most significant pathologies of 
asthma, including eosinophil and neutrophil recruitment, 
bronchial epithelial cell activation, mucus and collagen 
production and airway hyperactivity. These results, in as-
sociation with the low incidence of asthma in individuals 
with moderate dietary intake levels of quercetin, suggest 
that quercetin could be used medicinally, either alone or 
as a complement to other drugs currently used for the 
treatment of asthma. Additionally, it could also be used as 
a nutraceutical. Thus, clinical studies must be performed 
to evaluate the potential of quercetin to prevent or treat 
episodes of asthma in human patients.
LIST OF ABBREVIATIONS
AHR: airway hyperresponsiveness
ASA: acetylsalicylic acid
BALF: bronchoalveolar lavage fluids
BC: before Christ
CCL: chemokine (C-C motif) ligand
ERK: extracellular-signal-regulated kinase
FcεRI: high-affinity IgE Fc receptor 
ICAM-1: intercellular adhesion molecule-1
IFN-g: interferon gamma
Ig: immunoglobulin
IL: interleukin
JNK: c-Jun N-terminal kinase
LPS: lipopolysaccharides
LTB4: leukotriene B4
MAPK: mitogen-activated protein (MAP) kinases
MCP-1: monocyte chemoattractant protein 1
MMP: matrix metalloproteinase
NF-kB: nuclear factor-kB
NKT: natural killer T
p38 MAPK: P38 mitogen-activated protein kinase
PaCO2: pressure of carbon dioxide
PI3K: phosphatidylinositol (PI) 3-kinase
QU-ME: quercetin-loaded microemulsion
QU-SP: quercetin suspension
Th: T helper
TIMP: tissue inhibitor of metalloproteinase
TNF-α: tumour necrosis factor alpha
Treg: T regulatory cell
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